Pages that link to "Q28187904"
Jump to navigation
Jump to search
The following pages link to Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease (Q28187904):
Displaying 50 items.
- Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system (Q21090220) (← links)
- The promise of neuroprotective agents in Parkinson's disease (Q21129436) (← links)
- Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations (Q24289526) (← links)
- Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression (Q24339450) (← links)
- Available and emerging treatments for Parkinson’s disease: a review (Q24633444) (← links)
- Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies (Q24642726) (← links)
- The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment (Q24675617) (← links)
- Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives (Q26747508) (← links)
- Miniaturized Technologies for Enhancement of Motor Plasticity (Q26752338) (← links)
- Chronic, intermittent convection-enhanced delivery devices (Q26776237) (← links)
- Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. (Q26776474) (← links)
- GDNF-induced cerebellar toxicity: A brief review (Q26780274) (← links)
- The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease (Q26783362) (← links)
- Parkinson's disease: gene therapies (Q26824184) (← links)
- The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? (Q27023715) (← links)
- Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? (Q27024152) (← links)
- Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease (Q27320553) (← links)
- Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans (Q28067169) (← links)
- GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease (Q28088320) (← links)
- A specific survival response in dopamine neurons at most risk in Parkinson's disease (Q28115736) (← links)
- Parkinson's disease (Q28264391) (← links)
- Neurotrophic factors as a therapeutic target for Parkinson's disease (Q28273071) (← links)
- Biotechnology: Crossing the barrier (Q28291058) (← links)
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial (Q28296434) (← links)
- Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation (Q28298280) (← links)
- Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain (Q28486860) (← links)
- Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum (Q28488443) (← links)
- Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease (Q28580559) (← links)
- A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys (Q28728201) (← links)
- Dopamine neuron stimulating actions of a GDNF propeptide (Q28748465) (← links)
- A synopsis on the role of tyrosine hydroxylase in Parkinson's disease (Q28830946) (← links)
- Parkinson's disease: mechanisms and models (Q29547424) (← links)
- Parkinson's disease (Q29616302) (← links)
- Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo. (Q30387126) (← links)
- Metabotropic glutamate receptors: from the workbench to the bedside (Q30448778) (← links)
- Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid (Q30497736) (← links)
- Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys (Q30581632) (← links)
- Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease (Q30846057) (← links)
- Neuroimaging in Parkinson disease: from research setting to clinical practice (Q30868628) (← links)
- Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. (Q30982993) (← links)
- Imaging in cell-based therapy for neurodegenerative diseases. (Q31015455) (← links)
- Localized striatal delivery of GDNF as a treatment for Parkinson disease (Q31038741) (← links)
- Real-time imaging and quantification of brain delivery of liposomes (Q31061027) (← links)
- Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. (Q31141544) (← links)
- Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles (Q33327584) (← links)
- Generalized algorithms for direct reconstruction of parametric images from dynamic PET data (Q33446143) (← links)
- Future applications: gene therapy. (Q33474641) (← links)
- Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons (Q33492743) (← links)
- Convection-enhanced delivery of liposomes to primate brain. (Q33515945) (← links)
- Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease (Q33517934) (← links)